Click here for ReFacto AF® (moroctocog alfa) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.
ReFacto AF is administered by intravenous infusion over several minutes after reconstitution of the lyophilised powder for injection with sodium chloride 9 mg/ml (0.9%) solution for injection (provided). The rate of administration should be determined by the patient's comfort level.
ReFacto AF can be reconstituted and administered using our R2 or FuseNGo device.
We’ve created the ‘ReFacto AF R2 infusion mat’ and ‘ReFacto AF FuseNGo infusion mat’ as support materials for your patients. They provide a detailed and visual step-by-step guide on how to use each device.
In addition, we have also produced an informative leaflet for patients using the FuseNGo device.
You can download these materials for your patients by following the link below, or alternatively get in contact with the Pfizer Haemophilia team to request printed versions.
Speak to a member of the Pfizer Haemophilia team.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020